-
Actinium Pharmaceuticals Hits Key Milestones in Actimab-A Development and Listing Status
NYSEAMERICAN: $ATNM Advancing the Future of Targeted Radiotherapy Actinium Pharmaceuticals has recently shared significant updates regarding its lead program, Actimab-A, an antibody-radioisotope conjugate (ARC) designed to treat high-risk acute myeloid leukemia (AML). These developments mark a pivotal moment for the company’s clinical and commercial strategies. Intellectual Property and Manufacturing Success The company confirmed robust progress…
-
Actinium Pharmaceuticals Receives Two Patent Allowances Spanning Its Actimab-A and Iomab-ACT Programs
NYSEAMERICAN: $ATNM Source: Read More
-
Actinium | Highlights Broad Potential of Targeted Radiotherapies Iomab-B and Actimab-A for Relapsed or Refractory and Elderly Acute Myeloid Leukemia Patients at the 65th ASH Annual Meeting & Exposition
NYSE: $ATNM NEW YORK, Dec. 8, 2023 /PRNewswire/ — Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: $ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced that clinical data from its Iomab-B and Actimab-A programs will be featured in four presentations at the 65th Annual American Society of Hematology Annual Meeting &…